Markman Biologics Receives TRIP Letter

Markman Biologics Receives TRIP Letter
News provided by
Share this article
LAS VEGAS, April 26, 2021 /PRNewswire/ -- Markman Biologics Corporation (the "Company") (
https://markmanbiologics.com) today announces they have received our TRIP LETTER (Tissue Reference Group Rapid Inquiry Process). The TRIP response letter was received from the Food and Drug Administration (FDA), and specifically from the Center for Biologics Evaluation and Research (CBER) which provides confirmation of our regulatory status as a 361 HCT/P, and the documentation of that status is what is required to be provided for us to sell to the U.S. military.
Alan Shinderman, CEO of Markman Biologics Corporation, recently stated the dental study with the McGuire Group is 90% enrolled. We anticipate the results to be in by August. The study with the Burn Centers of America is continuing to recruit.

Related Keywords

Nevada ,United States ,America ,Alan Shinderman ,Markman Biologics ,Mcguire Group ,Prnewswire Markman Biologics Corporation The Company ,Drug Administration ,Markman Biologics Corporation ,Tissue Reference Group Rapid Inquiry ,Burn Centers Of America ,Biologics Corporation ,Tissue Reference Group Rapid Inquiry Process ,Biologics Evaluation ,Burn Centers ,Markman Biologic ,நெவாடா ,ஒன்றுபட்டது மாநிலங்களில் ,அமெரிக்கா ,மார்க்மேன் உயிரியல் ,மக்வைர் குழு ,மார்க்மேன் உயிரியல் நிறுவனம் ,உயிரியல் நிறுவனம் ,உயிரியல் மதிப்பீடு ,எரிக்க மையங்கள் ,